SCHEMBL5407477

SCHEMBL5407477

O=C(NCc1cccc(C(F)(F)F)c1)c1cc(-c2nc(Nc3ccccc3)ncc2-c2cc(Cl)cc(Cl)c2)c[nH]1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.48
AURKA O14965 4/20 0.48
CDK2 P24941 4/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLA2G1B P04054 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
MAPK1 P28482 4/20 0.46
MAPK10 P53779 1/20 0.46
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16893019 0.88 CNR2 (0.43) CNR2AURKACDK2MEN1KMT2A
SCHEMBL5407262 0.80 AURKA (0.51) AURKACDK2MAPK1
SCHEMBL5406880 0.70 AURKA (0.55) AURKACDK2MAPK1
SCHEMBL18073182 0.69 AURKA (0.64) AURKACDK2MAPK1MAPK10ROCK1
SCHEMBL6992727 0.68 AURKA (0.64) AURKACDK2MAPK1
SCHEMBL5405423 0.67 MAPK10 (0.45) MAPK1MAPK10
SCHEMBL5403707 0.67 AURKA (0.56) AURKACDK2MAPK1ROCK1
SCHEMBL5390985 0.67 AURKA (0.68) AURKACDK2MAPK1MAPK10ROCK1
SCHEMBL5083338 0.67 CNR2 (0.85) CNR2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4879066 0.66 ROCK2 (0.68) MEN1KMT2APLA2G1BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-6743791-B2 ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS VERTEX PHARMACEUTICALS INCORPORATED 2004-06-01 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 CNR2 117/4885AURKA 3692/4885CDK2 66/4885
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 CNR2 666/4885AURKA 1989/4885CDK2 9/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 CNR2 666/4885AURKA 1989/4885CDK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.